基于化学修饰新抗原的免疫治疗，针对KRASG12C驱动的肿瘤。
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors.
发表日期：2023 Mar 16
作者：
Mai Abdel Mouti, Siim Pauklin
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES
摘要：
KRAS G12C 目标治疗的临床疗效和持久性受到耐药机制的限制。在这里，我们提供最近使用共价修饰的肽/MHC I 类复合物作为肿瘤特异性新抗原的 KRAS G12C 目标治疗和免疫治疗统一策略的综述，以利用半胱氨酸基免疫治疗科技标记耐药癌细胞的毁灭。版权所有©2023作者。由爱思唯尔出版。保留所有权利。
The clinical efficacy and durability of KRASG12C-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRASG12C-targeted therapy and immunotherapy-unifying strategies that utilize covalently modified peptide/MHC class I complexes as tumor-specific neoantigens to tag drug-resistant cancer cells for destruction with hapten-based immunotherapeutics.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.